FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Peter Lachmann

Research Profile

Chemicals & Drugs

Co-author Network

Publications

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Peter Lachmann (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2011: Peter Lachmann
The grandmother effect.
Gerontology 2011;57(4):375-7.
2010: Peter Lachmann
Religion--an evolutionary adaptation.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2010;24(5):1301-7.
2010: Peter Lachmann
Preparing serum for functional complement assays.
Journal of immunological methods 2010;352(1-2):195-7.
2010: Peter Lachmann
An open letter to the health secretary: how to really save money on the NHS.
BMJ (Clinical research ed.) 2010;341():c5618.
2009: Peter Lachmann
Anti-infective antibodies--reviving an old paradigm.
Vaccine 2009;27 Suppl 6():G33-7.
2009: Peter Lachmann; R A G Smith
Taking complement to the clinic--has the time finally come?
Scandinavian journal of immunology 2009;69(6):471-8.
2009: Peter Lachmann
The amplification loop of the complement pathways.
Advances in immunology 2009;104():115-49.
2007: Barbara A Fernie-King; David J Seilly; Michael J Binks; Kadaba S Sriprakash; Peter Lachmann
Streptococcal DRS (distantly related to SIC) and SIC inhibit antimicrobial peptides, components of mucosal innate immunity: a comparison of their activities.
Microbes and infection / Institut Pasteur 2007;9(3):300-7.
2006: Barbara A Fernie-King; David J Seilly; Peter Lachmann
Inhibition of antimicrobial peptides by group A streptococci: SIC and DRS.
Biochemical Society transactions 2006;34(Pt 2):273-5.
2006: Peter Lachmann
Complement before molecular biology.
Molecular immunology 2006;43(6):496-508.
2006: Anthony P Manderson; Francesco Carlucci; Peter Lachmann; Robert A Lazarus; Richard J Festenstein; H Terence Cook; Mark J Walport; Marina Botto
The in vivo expression of actin/salt-resistant hyperactive DNase I inhibits the development of anti-ssDNA and anti-histone autoantibodies in a murine model of systemic lupus erythematosus.
Arthritis research & therapy 2006;8(3):R68.
2005: Michael J Binks; Barbara A Fernie-King; David J Seilly; Peter Lachmann; Kadaba S Sriprakash
Attribution of the various inhibitory actions of the streptococcal inhibitor of complement (SIC) to regions within the molecule.
The Journal of biological chemistry 2005;280(20):20120-5.
2004: Barbara A Fernie-King; David J Seilly; Peter Lachmann
The interaction of streptococcal inhibitor of complement (SIC) and its proteolytic fragments with the human beta defensins.
Immunology 2004;111(4):444-52.
2004: Pieter S Hiemstra; Barbara A Fernie-King; J McMichael; Peter Lachmann; J-M Sallenave
Antimicrobial peptides: mediators of innate immunity as templates for the development of novel anti-infective and immune therapeutics.
Current pharmaceutical design 2004;10(23):2891-905.
2003: A P G Landi; A B Wilson; Alexandra Davies; Peter Lachmann; Virginia P L Ferriani; David J Seilly; A I Assis-Pandochi
Determination of CD59 protein in normal human serum by enzyme immunoassay, using octyl-glucoside detergent to release glycosyl-phosphatidylinositol-CD59 from lipid complex.
Immunology letters 2003;90(2-3):209-13.
2003: Peter Lachmann
Consent and confidentiality--where are the limits? An introduction.
Journal of medical ethics 2003;29(1):2-3.
2003: Peter Lachmann
Lupus and desoxyribonuclease.
Lupus 2003;12(3):202-6.
2003: Peter Lachmann
Henry Kunkel.
Lupus 2003;12(3):200-1.
2002: Barbara A Fernie-King; David J Seilly; Alexandra Davies; Peter Lachmann
Subversion of the innate immune response by micro-organisms.
Annals of the rheumatic diseases 2002;61 Suppl 2():ii8-12.
2002: Peter Lachmann
Stem cell therapy: medical advance or moral challenge?
Comptes rendus biologies 2002;325(10):1049-51.
2002: Barbara A Fernie-King; David J Seilly; Alexandra Davies; Peter Lachmann
Streptococcal inhibitor of complement inhibits two additional components of the mucosal innate immune system: secretory leukocyte proteinase inhibitor and lysozyme.
Infection and immunity 2002;70(9):4908-16.
2002: Peter Lachmann
Microbial subversion of the immune response.
Proceedings of the National Academy of Sciences of the United States of America 2002;99(13):8461-2.
2002: P J Elliott; C J C Phillips; B Clayton; Peter Lachmann
The risk to the United Kingdom population of zinc cadmium sulfide dispersion by the Ministry of Defence during the "cold war".
Occupational and environmental medicine 2002;59(1):13-7.
2001: Gabriele Margos; S Navarette; Geoff A Butcher; Alexandra Davies; C Willers; Robert E Sinden; Peter Lachmann
Interaction between host complement and mosquito-midgut-stage Plasmodium berghei.
Infection and immunity 2001;69(8):5064-71.
2001: Barbara A Fernie-King; David J Seilly; C Willers; Reinhard Wurzner; Alexandra Davies; Peter Lachmann
Streptococcal inhibitor of complement (SIC) inhibits the membrane attack complex by preventing uptake of C567 onto cell membranes.
Immunology 2001;103(3):390-8.
2001: David Davis; H Trischmann; D M Stephens; Peter Lachmann
Antibodies raised to short synthetic peptides with sequences derived from HIV-1 SF2 gp120 can both neutralize and enhance HIV-1 SF13: a later variant isolated from the same host.
Journal of medical virology 2001;64(3):207-16.
2000: Wei Zhang; B Bi; R G Oldroyd; Peter Lachmann
Neutrophil lactoferrin release induced by IgA immune complexes differed from that induced by cross-linking of fcalpha receptors (FcalphaR) with a monoclonal antibody, MIP8a.
Clinical and experimental immunology 2000;121(1):106-11.
2000: Matthew C Pickering; Marina Botto; Philip R Taylor; Peter Lachmann; Mark J Walport
Systemic lupus erythematosus, complement deficiency, and apoptosis.
Advances in immunology 2000;76():227-324.
1999: M Macanovic; M B Hogarth; Peter Lachmann
Anti-DNA antibodies in the urine of lupus nephritis patients.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 1999;14(6):1418-24.
1999: Mark G Wing; David J Seilly; Richard S Nicholas; S Rahman; J Zajicek; Peter Lachmann; D A S Compston
Comparison of C1q-receptors on rat microglia and peritoneal macrophages.
Journal of neuroimmunology 1999;94(1-2):74-81.
1999: Peter Lachmann
The Lloyd Roberts Lecture. Immunopathology: past, present and future.
Transactions of the Medical Society of London 1999;116():18-30.
1998: Peter Lachmann
Public health and bioethics.
The Journal of medicine and philosophy 1998;23(3):297-302.
1998: C Agoropoulou; S J Piddlesden; Peter Lachmann; Mark G Wing
Neuronal protection of oligodendrocytes from antibody-independent complement lysis.
Neuroreport 1998;9(5):927-32.
1998: Peter Lachmann
Microbial immunology: a new mechanism for immune subversion.
Current biology : CB 1998;8(3):R99-R101.
1997: Peter Lachmann; A Davies
Complement and immunity to viruses.
Immunological reviews 1997;159():69-77.
1997: J K Voice; Peter Lachmann
Neutrophil Fc gamma and complement receptors involved in binding soluble IgG immune complexes and in specific granule release induced by soluble IgG immune complexes.
European journal of immunology 1997;27(10):2514-23.
1997: MJ Hobart; BA Fernie; Reinhard Wurzner; R G Oldroyd; R A Harrison; V Joysey; Peter Lachmann
Difficulties in the ascertainment of C9 deficiency: lessons to be drawn from a compound heterozygote C9-deficient subject.
Clinical and experimental immunology 1997;108(3):500-6.
1997: J C Bramley; Alexandra Davies; Peter Lachmann
Herpesvirus saimiri CD59--baculovirus expression and characterisation of complement inhibitory activity.
Biochemical Society transactions 1997;25(2):354S.
1997: W Zhang; Y M Lucisano; Peter Lachmann
Complement in IgA immune-complex-induced neutrophil activation.
Biochemical Society transactions 1997;25(2):462-6.
1997: M Macanovic; Peter Lachmann
Measurement of deoxyribonuclease I (DNase) in the serum and urine of systemic lupus erythematosus (SLE)-prone NZB/NZW mice by a new radial enzyme diffusion assay.
Clinical and experimental immunology 1997;108(2):220-6.
1996: Mark G Wing; T Moreau; J Greenwood; R M Smith; Geoff Hale; J Isaacs; Herman Waldmann; Peter Lachmann; Alastair Compston
Mechanism of first-dose cytokine-release syndrome by CAMPATH 1-H: involvement of CD16 (FcgammaRIII) and CD11a/CD18 (LFA-1) on NK cells.
The Journal of clinical investigation 1996;98(12):2819-26.
1996: M Macanovic; DV Sinicropi; S Shak; S Baughman; S Thiru; Peter Lachmann
The treatment of systemic lupus erythematosus (SLE) in NZB/W F1 hybrid mice; studies with recombinant murine DNase and with dexamethasone.
Clinical and experimental immunology 1996;106(2):243-52.
1996: Peter Lachmann
The in vivo destruction of antigen--a tool for probing and modulating an autoimmune response.
Clinical and experimental immunology 1996;106(2):187-9.
1996: BA Fernie; Reinhard Wurzner; Ann Orren; B P Morgan; Paul C Potter; Alexander E Platonov; Irina V Vershinina; German A Shipulin; Peter Lachmann; MJ Hobart
Molecular bases of combined subtotal deficiencies of C6 and C7: their effects in combination with other C6 and C7 deficiencies.
Journal of immunology (Baltimore, Md. : 1950) 1996;157(8):3648-57.
1996: J E Teixeira; R S Costa; Peter Lachmann; Reinhard Wurzner; J E Barbosa
CR1 stump peptide and terminal complement complexes are found in the glomeruli of lupus nephritis patients.
Clinical and experimental immunology 1996;105(3):497-503.
1996: Reinhard Wurzner; Alexander E Platonov; V B Beloborodov; A I Pereverzev; Irina V Vershinina; BA Fernie; MJ Hobart; Peter Lachmann; Ann Orren
How partial C7 deficiency with chronic and recurrent bacterial infections can mimic total C7 deficiency: temporary restoration of host C7 levels following plasma transfusion.
Immunology 1996;88(3):407-11.
1996: Jan Torzewski; R Oldroyd; Peter Lachmann; Colin M Fitzsimmons; Diane Proudfoot; David E Bowyer
Complement-induced release of monocyte chemotactic protein-1 from human smooth muscle cells. A possible initiating event in atherosclerotic lesion formation.
Arteriosclerosis, thrombosis, and vascular biology 1996;16(5):673-7.
1996: W Zhang; Peter Lachmann
Neutrophil lactoferrin release induced by IgA immune complexes can be mediated either by Fc alpha receptors or by complement receptors through different pathways.
Journal of immunology (Baltimore, Md. : 1950) 1996;156(7):2599-606.
1996: Peter Lachmann
Current topics in complement research.
Research in immunology 1996;147(2):69-70.
1995: SM McHugh; John Deighton; A G Stewart; Peter Lachmann; Pamela W Ewan
Bee venom immunotherapy induces a shift in cytokine responses from a TH-2 to a TH-1 dominant pattern: comparison of rush and conventional immunotherapy.
Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology 1995;25(9):828-38.
1995: W Zhang; J Voice; Peter Lachmann
A systematic study of neutrophil degranulation and respiratory burst in vitro by defined immune complexes.
Clinical and experimental immunology 1995;101(3):507-14.
1995: Reinhard Wurzner; D Mewar; BA Fernie; MJ Hobart; Peter Lachmann
Importance of the third thrombospondin repeat of C6 for terminal complement complex assembly.
Immunology 1995;85(2):214-9.
1995: A Davies; A B Wilson; J C Bramley; C Willers; Veronica van Heyningen; W A Bickmore; Peter Lachmann
Identification of MIC 11 antigen as an epitope of the CD59 molecule.
Immunology 1995;85(2):220-7.
1995: Reinhard Wurzner; BA Fernie; A M Jones; Peter Lachmann; MJ Hobart
Molecular basis of the complement C7 M/N polymorphism. A neutral amino acid substitution outside the epitope of the allospecific monoclonal antibody WU 4-15.
Journal of immunology (Baltimore, Md. : 1950) 1995;154(9):4813-9.
1995: A M Ferreira; Reinhard Wurzner; MJ Hobart; Peter Lachmann
Study of the in vitro activation of the complement alternative pathway by Echinococcus granulosus hydatid cyst fluid.
Parasite immunology 1995;17(5):245-51.
1995: BA Fernie; Ann Orren; Reinhard Wurzner; A M Jones; Paul C Potter; Peter Lachmann; MJ Hobart
Complement component C6 and C7 haplotypes associated with deficiencies of C6.
Annals of human genetics 1995;59(Pt 2):183-95.
1995: Reinhard Wurzner; MJ Hobart; BA Fernie; D Mewar; Paul C Potter; Ann Orren; Peter Lachmann
Molecular basis of subtotal complement C6 deficiency. A carboxy-terminally truncated but functionally active C6.
The Journal of clinical investigation 1995;95(4):1877-83.
1995: H Trischmann; D Davis; Peter Lachmann
Lymphocytotropic strains of HIV type 1 when complexed with enhancing antibodies can infect macrophages via Fc gamma RIII, independently of CD4.
AIDS research and human retroviruses 1995;11(3):343-52.
1995: SM McHugh; I R Rifkin; John Deighton; A B Wilson; Peter Lachmann; C M Lockwood; Pamela W Ewan
The immunosuppressive drug thalidomide induces T helper cell type 2 (Th2) and concomitantly inhibits Th1 cytokine production in mitogen- and antigen-stimulated human peripheral blood mononuclear cell cultures.
Clinical and experimental immunology 1995;99(2):160-7.
1994: Yasuhiro Takeuchi; F L Cosset; Peter Lachmann; H Okada; Robin A Weiss; Mary K Collins
Type C retrovirus inactivation by human complement is determined by both the viral genome and the producer cell.
Journal of virology 1994;68(12):8001-7.
1994: SM McHugh; A B Wilson; John Deighton; Peter Lachmann; Pamela W Ewan
The profiles of interleukin (IL)-2, IL-6, and interferon-gamma production by peripheral blood mononuclear cells from house-dust-mite-allergic patients: a role for IL-6 in allergic disease.
Allergy 1994;49(9):751-9.
1994: Ann Orren; Reinhard Wurzner; Peter Lachmann; MJ Hobart
A novel human complement component C7 phenotype detected in South Africa and proposed designation of the allele as C7*10.
European journal of immunogenetics : official journal of the British Society for Histocompatibility and Immunogenetics 1994;21(3):181-7.
1994: Reinhard Wurzner; V C Joysey; Peter Lachmann
Complement component C7. Assessment of in vivo synthesis after liver transplantation reveals that hepatocytes do not synthesize the majority of human C7.
Journal of immunology (Baltimore, Md. : 1950) 1994;152(9):4624-9.
1994: M Parizade; Ruth Arnon; Peter Lachmann; Zvi Fishelson
Functional and antigenic similarities between a 94-kD protein of Schistosoma mansoni (SCIP-1) and human CD59.
The Journal of experimental medicine 1994;179(5):1625-36.
1994: A B Wilson; John Deighton; Peter Lachmann; Pamela W Ewan
A comparative study of IgG subclass antibodies in patients allergic to wasp or bee venom.
Allergy 1994;49(4):272-80.
1994: C M Fletcher; R A Harrison; Peter Lachmann; David Neuhaus
Structure of a soluble, glycosylated form of the human complement regulatory protein CD59.
Structure (London, England : 1993) 1994;2(3):185-99.
1994: BA Fernie; MJ Hobart; G Delbridge; Paul C Potter; Ann Orren; Peter Lachmann
C6 haplotypes: associations of a Dde I site polymorphism to complement deficiency genes and the Msp I restriction fragment length polymorphism (RFLP)
Clinical and experimental immunology 1994;95(2):351-6.
1994: Peter Lachmann
The biology of complement. Introduction.
Springer seminars in immunopathology 1994;15(4):303-6.
1994: Alexander E Platonov; Reinhard Wurzner; B Beloborodov; A M Jones; D V Troshansky; Irina V Vershinina; Peter Lachmann; Ann Orren
Paradoxical reconstitution of complement activity following plasma transfusion of an individual with deficiency of the seventh component of complement.
Immunology 1994;81(1):142-8.
1994: W Zhang; Peter Lachmann
Glycosylation of IgA is required for optimal activation of the alternative complement pathway by immune complexes.
Immunology 1994;81(1):137-41.
1993: D J Unsworth; Reinhard Wurzner; D L Brown; Peter Lachmann
Extracts of wheat gluten activate complement via the alternative pathway.
Clinical and experimental immunology 1993;94(3):539-43.
1993: C M Fletcher; R A Harrison; Peter Lachmann; David Neuhaus
Sequence-specific 1H-NMR assignments and folding topology of human CD59.
Protein science : a publication of the Protein Society 1993;2(12):2015-27.
1993: David Davis; D M Stephens; C A Carne; Peter Lachmann
Antisera raised against the second variable region of the external envelope glycoprotein of human immunodeficiency virus type 1 cross-neutralize and show an increased neutralization index when they act together with antisera to the V3 neutralization epitope.
The Journal of general virology 1993;74 ( Pt 12)():2609-17.
1993: P M Clissold; H J Ebling; Peter Lachmann
Construction, expression and functional analysis of a glycolipid-linked form of CR1.
European journal of immunology 1993;23(9):2346-52.
1993: W Zhang; Pamela W Ewan; Peter Lachmann
The paraproteins in systemic capillary leak syndrome.
Clinical and experimental immunology 1993;93(3):424-9.
1993: Pamela W Ewan; John Deighton; A B Wilson; Peter Lachmann
Venom-specific IgG antibodies in bee and wasp allergy: lack of correlation with protection from stings.
Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology 1993;23(8):647-60.
1993: MJ Hobart; BA Fernie; R G DiScipio; Peter Lachmann
A physical map of the C6 and C7 complement component gene region on chromosome 5p13.
Human molecular genetics 1993;2(7):1035-6.
1993: A B Wilson; SM McHugh; John Deighton; Pamela W Ewan; Peter Lachmann
A competitive inhibition ELISA for the quantification of human interferon-gamma.
Journal of immunological methods 1993;162(2):247-55.
1993: Peter W Mathieson; Reinhard Wurzner; D B Oliveria; Peter Lachmann; D K Peters
Complement-mediated adipocyte lysis by nephritic factor sera.
The Journal of experimental medicine 1993;177(6):1827-31.
1993: MJ Hobart; BA Fernie; K K Stanley; Peter Lachmann
C6 epitope expression by an unrelated antisense cDNA clone: an inadvertent surface-simulation mimotope.
Proceedings. Biological sciences / The Royal Society 1993;252(1334):157-62.
1993: SM McHugh; Peter Lachmann; Pamela W Ewan
Peripheral blood mononuclear cells from house dust mite allergic patients produce IL-2 in response to specific allergen challenge.
Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology 1993;23(2):137-44.
1993: A Davies; Peter Lachmann
Membrane defence against complement lysis: the structure and biological properties of CD59.
Immunologic research 1993;12(3):258-75.
1992: Ann Orren; R E Warren; Paul C Potter; A M Jones; Peter Lachmann; J T Poolman
Antibodies to meningococcal class 1 outer membrane proteins in South African complement-deficient and complement-sufficient subjects.
Infection and immunity 1992;60(11):4510-6.
1992: Reinhard Wurzner; N Rance; Paul C Potter; M L Hendricks; Peter Lachmann; Ann Orren
C7 M/N protein polymorphism typing applied to inherited deficiencies of human complement proteins C6 and C7.
Clinical and experimental immunology 1992;89(3):485-9.
1992: MJ Hobart; BA Fernie; Peter Lachmann
A cleavable biotinylating agent and its use in protein electroblots.
Journal of immunological methods 1992;153(1-2):93-8.
1992: Peter Lachmann
The Seventh K Prathap Memorial Lecture. The pathogenesis of autoimmune immune complex disease.
The Malaysian journal of pathology 1992;14(1):1-5.
1992: Mark G Wing; John Zajicek; D J Seilly; D A S Compston; Peter Lachmann
Oligodendrocytes lack glycolipid anchored proteins which protect them against complement lysis. Restoration of resistance to lysis by incorporation of CD59.
Immunology 1992;76(1):140-5.
1992: D M Stephens; J W Eichberg; Nancy Haigwood; K S Steimer; David Davis; Peter Lachmann
Antibodies are produced to the variable regions of the external envelope glycoprotein of human immunodeficiency virus type 1 in chimpanzees infected with the virus and baboons immunized with a candidate recombinant vaccine.
The Journal of general virology 1992;73 ( Pt 5)():1099-106.
1992: John Zajicek; Mark G Wing; Peter Lachmann; D A S Compston
Mechanisms of oligodendrocyte interaction with normal human serum--defining the role of complement.
Journal of the neurological sciences 1992;108(1):65-72.
1992: W D Ratnoff; jansen knez; G M Prince; H Okada; Peter Lachmann; M Edward Medof
Structural properties of the glycoplasmanylinositol anchor phospholipid of the complement membrane attack complex inhibitor CD59.
Clinical and experimental immunology 1992;87(3):415-21.
1992: A M Montgomery; Mark G Wing; Peter Lachmann
The targeting of T-helper cells and tumourcidal macrophages to a B-cell lymphoma using a PPD-monoclonal antibody heteroconjugate.
Immunology 1992;75(2):217-23.
1992: Reinhard Wurzner; MJ Hobart; Ann Orren; K Tokunaga; R Nitze; Otto Götze; Peter Lachmann
A novel protein polymorphism of human complement C7 detected by a monoclonal antibody.
Immunogenetics 1992;35(6):398-402.
1992: Reinhard Wurzner; Ann Orren; Peter Lachmann
Inherited deficiencies of the terminal components of human complement.
Immunodeficiency reviews 1992;3(2):123-47.
1992: Ann Orren; Reinhard Wurzner; Paul C Potter; BA Fernie; S Coetzee; B P Morgan; Peter Lachmann
Properties of a low molecular weight complement component C6 found in human subjects with subtotal C6 deficiency.
Immunology 1992;75(1):10-6.
1992: J E Barbosa; R A Harrison; P J Barker; Peter Lachmann
An anti-peptide antibody that recognizes a neo-antigen in the CR1 stump remaining on erythrocytes after proteolysis.
Clinical and experimental immunology 1992;87(1):144-9.
1991: Seppo Meri; H Waldmann; Peter Lachmann
Distribution of protectin (CD59), a complement membrane attack inhibitor, in normal human tissues.
Laboratory investigation; a journal of technical methods and pathology 1991;65(5):532-7.
1991: Peter Lachmann
The control of homologous lysis.
Immunology today 1991;12(9):312-5.
1991: Y M Lucisano Valim; Peter Lachmann
The effect of antibody isotype and antigenic epitope density on the complement-fixing activity of immune complexes: a systematic study using chimaeric anti-NIP antibodies with human Fc regions.
Clinical and experimental immunology 1991;84(1):1-8.
1991: I A Rooney; A Davies; D Griffiths; John D Williams; Malcolm Davies; S Meri; Peter Lachmann; B Paul Morgan
The complement-inhibiting protein, protectin (CD59 antigen), is present and functionally active on glomerular epithelial cells.
Clinical and experimental immunology 1991;83(2):251-6.
1991: Reinhard Wurzner; K Tokunaga; R Nitze; Otto Götze; Peter Lachmann
C7*N is a hypomorphic allele of the human complement c7 M/N protein polymorphism.
Experimental and clinical immunogenetics 1991;8(3):177-83.
1990: Peter Lachmann
Complement genetics and host defence.
Zentralblatt für Bakteriologie : international journal of medical microbiology 1990;274(3):316-24.
1990: Peter Lachmann
Protection against complement lysis.
Biochemical Society transactions 1990;18(6):1159-60.
1990: Peter Lachmann
Biological functions of the complement system.
Biochemical Society transactions 1990;18(6):1143-5.
1990: David Davis; D M Stephens; C Willers; Peter Lachmann
Glycosylation governs the binding of antipeptide antibodies to regions of hypervariable amino acid sequence within recombinant gp120 of human immunodeficiency virus type 1.
The Journal of general virology 1990;71 ( Pt 12)():2889-98.
1990: A M Montgomery; Mark G Wing; Peter Lachmann
A novel strategy for targeting CD4+ PPD-reactive T cells against tumour cells using PPD monoclonal antibody heteroconjugates.
Clinical and experimental immunology 1990;82(2):200-7.
1990: Mark G Wing; A M Montgomery; C Harley; Peter Lachmann
Cytostasis of different tumours by a murine PPD-reactive CD4+ T lymphocyte clone is mediated by interferon-gamma and tumour necrosis factor alone or synergistically.
Clinical and experimental immunology 1990;82(2):208-13.
1990: M Harboe; Harald Gotten Wiker; Peter Lachmann
Carrier effect of concanavalin A-reactive and -non-reactive material in tuberculin PPD.
Scandinavian journal of immunology 1990;32(3):263-71.
1990: David Davis; B Chaudhri; D M Stephens; C A Carne; C Willers; Peter Lachmann
The immunodominance of epitopes within the transmembrane protein (gp41) of human immunodeficiency virus type 1 may be determined by the host's previous exposure to similar epitopes on unrelated antigens.
The Journal of general virology 1990;71 ( Pt 9)():1975-83.
1990: S Meri; B P Morgan; A Davies; R H Daniels; M G Olavesen; Herman Waldmann; Peter Lachmann
Human protectin (CD59), an 18,000-20,000 MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers.
Immunology 1990;71(1):1-9.
1990: Stephen J Perkins; K F Smith; S Amatayakul; D Ashford; T W Rademacher; Raymond A Dwek; Peter Lachmann; R A Harrison
Two-domain structure of the native and reactive centre cleaved forms of C1 inhibitor of human complement by neutron scattering.
Journal of molecular biology 1990;214(3):751-63.
1990: Mark J Walport; Peter Lachmann
Complement deficiencies and abnormalities of the complement system in systemic lupus erythematosus and related disorders.
Current opinion in rheumatology 1990;2(4):661-3.
1990: S Meri; B P Morgan; Mark G Wing; J Jones; A Davies; Eckhard R Podack; Peter Lachmann
Human protectin (CD59), an 18-20-kD homologous complement restriction factor, does not restrict perforin-mediated lysis.
The Journal of experimental medicine 1990;172(1):367-70.
1990: S Songsivilai; Peter Lachmann
Antibody engineering: current status and future development.
Asian Pacific journal of allergy and immunology / launched by the Allergy and Immunology Society of Thailand 1990;8(1):53-60.
1990: S Songsivilai; Peter Lachmann
Bispecific antibody: a tool for diagnosis and treatment of disease.
Clinical and experimental immunology 1990;79(3):315-21.
1990: P Peake; M Szelke; D M Jones; A Singleton; J Sueiras-Diaz; Peter Lachmann
Peptide inhibitors of C3 breakdown.
Clinical and experimental immunology 1990;79(3):454-8.
1990: Stephen J Perkins; K F Smith; A S Nealis; Peter Lachmann; R A Harrison
Structural homologies of component C5 of human complement with components C3 and C4 by neutron scattering.
Biochemistry 1990;29(5):175-80.
1990: P A Gatenby; J E Barbosa; Peter Lachmann
Differences between C4A and C4B in the handling of immune complexes: the enhancement of CR1 binding is more important than the inhibition of immunoprecipitation.
Clinical and experimental immunology 1990;79(2):158-63.
1990: Peter Lachmann
Complement deficiency and the pathogenesis of autoimmune immune complex disease.
Chemical immunology 1990;49():245-63.
1989: M C Poznansky; P M Clissold; Peter Lachmann
The difference between human C3F and C3S results from a single amino acid change from an asparagine to an aspartate residue at position 1216 on the alpha chain of the complement component, C3.
Journal of immunology (Baltimore, Md. : 1950) 1989;143(11):3860-2.
1989: D E McFarlin; Peter Lachmann
Multiple sclerosis. Hopeful genes and immunology.
Nature 1989;341(6244):693-4.
1989: S Songsivilai; P M Clissold; Peter Lachmann
A novel strategy for producing chimeric bispecific antibodies by gene transfection.
Biochemical and biophysical research communications 1989;164(1):271-6.
1989: A Davies; D L Simmons; G Hale; R A Harrison; H Tighe; Peter Lachmann; H Waldmann
CD59, an LY-6-like protein expressed in human lymphoid cells, regulates the action of the complement membrane attack complex on homologous cells.
The Journal of experimental medicine 1989;170(3):637-54.
1989: T Mizuochi; RW Loveless; Alexander M Lawson; Wengang Chai; Peter Lachmann; Robert A Childs; S Thiel; Ten Feizi
A library of oligosaccharide probes (neoglycolipids) from N-glycosylated proteins reveals that conglutinin binds to certain complex-type as well as high mannose-type oligosaccharide chains.
The Journal of biological chemistry 1989;264(23):13834-9.
1989: Peter Lachmann
Molecular genetics of muscle disease--Duchenne and other dystrophies. Future prospects.
British medical bulletin 1989;45(3):819-24.
1989: W Emlen; G Burdick; V Carl; Peter Lachmann
Binding of model immune complexes to erythrocyte CR1 facilitates immune complex uptake by U937 cells.
Journal of immunology (Baltimore, Md. : 1950) 1989;142(12):4366-71.
1989: P A Pemberton; R A Harrison; Peter Lachmann; Robin W Carrell
The structural basis for neutrophil inactivation of C1 inhibitor.
The Biochemical journal 1989;258(1):193-8.
1989: RW Loveless; Ten Feizi; Robert A Childs; T Mizuochi; M S Stoll; R G Oldroyd; Peter Lachmann
Bovine serum conglutinin is a lectin which binds non-reducing terminal N-acetylglucosamine, mannose and fucose residues.
The Biochemical journal 1989;258(1):109-13.
1989: Peter Garred; Tom Eirik Mollnes; T Lea; Peter Lachmann
Enzyme immunoassay detection of circulating immune complexes by monoclonal antibodies to C3 neoepitopes with special reference to IgG concentration and to interfering anti-immunoglobulin antibodies.
Journal of immunological methods 1989;117(1):59-66.
1988: P Bird; Peter Lachmann
The regulation of IgG subclass production in man: low serum IgG4 in inherited deficiencies of the classical pathway of C3 activation.
European journal of immunology 1988;18(8):1217-22.
1988: T C Farries; Peter Lachmann; R A Harrison
Analysis of the interaction between properdin and factor B, components of the alternative-pathway C3 convertase of complement.
The Biochemical journal 1988;253(3):667-75.
1988: K S Aulak; P A Pemberton; F S Rosen; R W Carrell; Peter Lachmann; R A Harrison
Dysfunctional C1-inhibitor(At), isolated from a type II hereditary-angio-oedema plasma, contains a P1 'reactive centre' (Arg444----His) mutation.
The Biochemical journal 1988;253(2):615-8.
1988: Peter Lachmann
Complement and disease.
Recenti progressi in medicina 1988;79(7-8):293-9.
1982: A B Wilson; S Prichard-Thomas; B W Gurner; Peter Lachmann; R R Coombs
Complement components on human lymphocytes.
Clinical immunology and immunopathology 1982;22(1):118-27.
1980: A B Wilson; S Prichard-Thomas; Peter Lachmann; R R Coombs
Receptors on guinea-pig erythrocytes specific for cell-bound fourth component of human complement (C4).
Immunology 1980;39(2):195-202.
1980: R R Coombs; A B Wilson; Peter Lachmann
The coagglutination phenomenon of Bordet and Gengou involves a reaction between antibody-aggregated fourth component of complement and a receptor on guniea pig red cells.
International archives of allergy and applied immunology 1980;61(4):371-9.
1973: P A Nicol; Peter Lachmann
The alternate pathway of complement activation. The role of C3 and its inactivator (KAF).
Immunology 1973;24(2):259-75.